Wskazówki Polskiego Towarzystwa Chorób Płuc dotyczące metod pozyskiwania, opracowywania oraz oceny płynu z płukania oskrzelowo-pęcherzykowego (BAL)

Chciałowski, Andrzej; Chorostowska-Wynimko, Joanna; Wandalsen, Gustavo Falbo; Pawłowicz, Robert; Domagała‐Kulawik, Joanna

doi:10.5603/arm.27675

Cited by 10 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During FOB, BAL was performed according to ERS and Polish Respiratory Society guidelines [ 38 , 39 ]. BAL site was based on HRCT, and areas with the most evident involvement of the interstitial tissue were chosen.…”

Section: Methodsmentioning

confidence: 99%

Are There Differences in Inflammatory and Fibrotic Pathways between IPAF, CTD-ILDs, and IIPs? A Single-Center Pilot Study

Rzepka-Wrona¹,

Skoczyński²,

Barczyk³

2022

IJMS

View full text Add to dashboard Cite

In this pilot study, we aim to determine differences in pathogenetic pathways between interstitial pneumonia with autoimmune features (IPAF), connective-tissue-disease-associated interstitial lung diseases (CTD-ILDs), and idiopathic interstitial pneumonias (IIPs). Forty participants were recruited: 9 with IPAF, 15 with CTD-ILDs, and 16 with IIPs. Concentration of transforming growth factor beta (TGF-β1), surfactant proteins A and D (SP-A, SP-D), interleukin 8 (IL-8), and chemokine 1 (CXCL1) were assessed with ELISA assay in bronchoalveolar lavage (BAL) fluid. We revealed that IL-8 and TGF-β1 concentrations were significantly lower in the IPAF group than in the CTD-ILD group (p = 0.008 and p = 0.019, respectively), but similar to the concentrations in the IIP group. There were significant correlations of IL-8 (rs = 0.46; p = 0.003) and CXCL1 (rs = 0.52; p = 0.001) and BAL total cell count (TCC). A multivariate regression model revealed that IL-8 (β = 0.32; p = 0.037) and CXCL1 (β = 0.45; p = 0.004) are significant predictors of BAL TCC. We revealed that IL-8 and TGF-β1 BAL concentrations vary in patients with different ILDs and found that IL-8 is a predictor of BAL TCC in IPAF. However, this needs to be confirmed in a multicenter cooperative study (ClinicalTrials.gov Identifier: NCT03870828).

show abstract

Section: Methodsmentioning

confidence: 99%

Are There Differences in Inflammatory and Fibrotic Pathways between IPAF, CTD-ILDs, and IIPs? A Single-Center Pilot Study

Rzepka-Wrona¹,

Skoczyński²,

Barczyk³

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…BAL will be performed according to the guidelines of the ERS [8] and the practical guidelines of the Polish Respiratory Society [9]. A differential cell count will be performed in every sample.…”

Section: Fiberoptic Bronchoscopy With Bronchoalveolar Lavage and Bron...mentioning

confidence: 99%

“…A differential cell count will be performed in every sample. BALF samples will be processed by an experienced laboratory technician based on Polish Respiratory Society guidelines [9]. Microscopic slide preparation, determination of cell viability, and determination of the dominant population will be performed according to standard laboratory procedures in the Polish Respiratory Society guidelines.…”

Section: Fiberoptic Bronchoscopy With Bronchoalveolar Lavage and Bron...mentioning

confidence: 99%

Characteristics of Interstitial Pneumonia With Autoimmune Features (IPAF): Protocol for a Multicenter Prospective Study

Rzepka-Wrona¹,

Skoczyński²,

Piotrowski³

et al. 2023

JMIR Res Protoc

View full text Add to dashboard Cite

Background “Interstitial lung disease” (ILD) is a broad term encompassing diseases of different backgrounds. “Interstitial pneumonia with autoimmune features” (IPAF) is a recent term that implies the presence of autoimmunity. Objective This study aims to determine the characteristics of Polish patients with IPAF, compare them with patients with other interstitial pneumonias, and search for the prognostic and diagnostic biomarkers of IPAF in serum and bronchoalveolar lavage fluid (BALF). Methods This multicenter prospective study plans to recruit 240 participants divided into 1 study group and 2 control groups. Biological fluid samples will be collected according to Polish Respiratory Society management guidelines and stored at –80°C for further tests. Prospective 5-year observations of 60 newly diagnosed individuals are planned. The study will be divided into subsections. First, we plan to characterize Polish patients with IPAF (study group) against their peers with other ILDs (2 control groups). Control group 1 will comprise patients with idiopathic ILDs, including mainly idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Control group 2 will comprise patients with connective tissue disease–associated interstitial lung diseases, such as rheumatoid arthritis, systemic sclerosis, polymyositis, dermatomyositis, Sjögren’s syndrome, mixed connective tissue disease, and systemic lupus erythematosus. Radiological and functional parameters will be analyzed. Patients will be compared in terms of high-resolution computed tomography results, the 6-minute walking test performance, and pulmonary function test parameters. The diagnosis of IPAF will be reassessed on a regular basis through multidisciplinary discussion in order to determine its clinical stability. In the laboratory arm, inflammation and fibrosis pathways will be assessed. Cytokine levels (interleukin 8, transforming growth factor beta 1, chemokine C-C motif ligand [CXCL]18, CXCL1, surfactant protein [SP]-A, SP-D, Krebs von den Lungen-6 protein, and chitinase 1) will be measured in serum and BALF. A comparative analysis of serum and BALF cytokine levels will be performed in order to establish potential differences between systemic and local inflammatory pathways. In the quality of life (QoL) arm of the study, dyspnea and cough and their impact on various aspects of the QoL will be assessed. Depression and anxiety will be measured with the Hospital Anxiety and Depression Modified Scale and the 9-item Patient Health Questionnaire, and potential correlations with symptom prevalence will be assessed. Results This study will start recruiting patients to phase 1 in October 2023. The final results will be available in 2028. We plan to publish preliminary results after 2-3 years from the start of phase 1. Conclusions This study will be a step toward a better understanding of IPAF etiopathogenesis and outcomes. International Registered Report Identifier (IRRID) PRR1-10.2196/44802

show abstract

Expression of HIF-1A/VEGF/ING-4 Axis in Pulmonary Sarcoidosis

Piotrowski

Kiszałkiewicz

Pastuszak-Lewandoska

et al. 2015

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Angiogenesis/angiostasis regulated by hypoxia inducible factor-1A (HIF-1A)/vascular endothelial growth factor (VEGF)/inhibitor of growth protein 4 (ING-4) axis may be crucial for the course and outcome of sarcoidosis. Overexpression of angiogenic factors (activation of VEGF through HIF-1A) may predispose to chronic course and lung fibrosis, whereas immunoangiostasis (related to an overexpression of inhibitory ING-4) may be involved in granuloma formation in early sarcoid inflammation, or sustained or recurrent formation of granulomas. In this work we investigated gene expression of HIF-1A, VEGF and ING-4 in bronchoalveolar fluid (BALF) cells and in peripheral blood (PB) lymphocytes of sarcoidosis patients (n=94), to better understand mechanisms of the disease and to search for its biomarkers. The relative gene expression level (RQ value) was analyzed by qPCR. The results were evaluated according to the presence of lung parenchymal involvement (radiological stage I vs. II-IV), acute vs. insidious onset, lung function tests, calcium metabolism parameters, percentage of lymphocytes (BALL%) and BAL CD4+/CD8+ in BALF, age, and gender. In BALF cells, the ING-4 and VEGF RQ values were increased, while HIF-1A expression was decreased. In PB lymphocytes all studied genes were overexpressed. Higher expression of HIF-1A in PB lymphocytes of patients with abnormal spirometry, and in BALF cells of patients with lung volume restriction was found. VEGF gene expression in BALF cells was also higher in patients with abnormal spirometry. These findings were in line with previous data on the role of HIF-1A/VEGF/ING-4 axis in the pathogenesis of sarcoidosis. Up-regulated HIF-1A and VEGF genes are linked to acknowledged negative prognostics.

show abstract

Wskazówki Polskiego Towarzystwa Chorób Płuc dotyczące metod pozyskiwania, opracowywania oraz oceny płynu z płukania oskrzelowo-pęcherzykowego (BAL)

Cited by 10 publications

References 42 publications

Are There Differences in Inflammatory and Fibrotic Pathways between IPAF, CTD-ILDs, and IIPs? A Single-Center Pilot Study

Are There Differences in Inflammatory and Fibrotic Pathways between IPAF, CTD-ILDs, and IIPs? A Single-Center Pilot Study

Characteristics of Interstitial Pneumonia With Autoimmune Features (IPAF): Protocol for a Multicenter Prospective Study

Expression of HIF-1A/VEGF/ING-4 Axis in Pulmonary Sarcoidosis

Contact Info

Product

Resources

About